Upconversion emission from erbium doped sol-gel derived ВаТiOз powders and coatings

Upconversion is a process where light can be emitted with photon energies higher than those of the light generating the excitation (www.rp-photonics.com/upconversion). Diverse inorganic matrices doped with trivalent lanthanides - erbium and holmium exhibit upconversion, transferring infrared light into visible. Thus the effect attracts attention for detection and visualization of infrared radiation. Recently we reported that sol-gel derived barium titanate possessing refractive index about 1.9 in amorphous state can be used as component of optical interference filter in combination with low refractive index films as silica or magnesium fluoride. At the same time room-temperature luminescence of lanthanides in sol-gel derived barium titanate makes the material and method promising for light conversion. In this work we investigate erbium upconversion emission from sol-gel derived BaTiO3 films and powders

Influence of different chromosomal abnormalities in Ph-positive bone marrow cells on the chronic myeloid leukemia course during tyrosine kinase inhibitors therapy

The additional molecular and chromosomal abnormalities (ACA) in Phositive cells usually considered as a genetic marker of chronic myeloid leukemia (CML) progression. 457 patients in different CML phases received tyrosine kinase inhibitors (1st and 2nd generation) were studied. During therapy 50 cases with additional chromosomal abnormalities in Ph+ clone (22 of them in chronic CML phase) were revealed (median follow-up from CML diagnosis – 117 months, median imatinib therapy – 62 months). 86 % of patients in chronic phase with Ph+- cell abnormalities were cytogenetic resistance, and their 5-years overall survival was 80 % which was significantly lower than in patients without ACA (p &lt; 0.005). The treatment results depend on chromosomal abnormalities detected. In patients with additional chromosome 8 imatinib therapy is effective, although complete cytogenetic response (CCR) is achieved only in the later therapy stages. In patients with additional translocations CCR also achieved with imatinib or 2nd generation TKI. Only a third of patients with additional Ph-chromosome or BCR/ABL amplification achieved complete suppression of Ph+ clone using 2nd generation TKI. The presence of additional chromosome 7 abnormalities and complex karyotype disorders involving isochromosome i(17)(q10) are poor prognostic factors of TKI treatment failures.</p